Oruka Therapeutics, Inc. (ORKA)
ORKA Stock Up More Than 60% in 3 Months: Here's What You Should Know
Oruka's three-month rally reflects investor confidence in ORKA-001, with key clinical data and pipeline milestones scheduled ahead.
Oruka Therapeutics, Inc. (ORKA) Upgraded to Buy: What Does It Mean for the Stock?
Oruka Therapeutics, Inc. (ORKA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Wall Street Analysts Believe Oruka Therapeutics, Inc. (ORKA) Could Rally 111.13%: Here's is How to Trade
The mean of analysts' price targets for Oruka Therapeutics, Inc. (ORKA) points to an 111.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Oruka Therapeutics, Inc. (ORKA) Discusses Interim Results From EVERLAST-A Study of ORKA-001 in Moderate to Severe Plaque Psoriasis Transcript
Oruka Therapeutics, Inc. (ORKA) Discusses Interim Results From EVERLAST-A Study of ORKA-001 in Moderate to Severe Plaque Psoriasis Transcript
Oruka Therapeutics: 'Strong Buy' On Half-Life Extended IL-23p19 Inhibitor ORKA-001
Oruka Therapeutics (ORKA) earns a "Strong Buy" rating after positive phase 2a interim results for ORKA-001 in moderate-to-severe plaque psoriasis. ORKA-001's half-life extension technology targets once-yearly dosing, aiming for best-in-class efficacy and competitive differentiation in a crowded biologics market. Key near-term catalysts include longer-term phase 2a follow-up data in H2 2026 and phase 2b EVERLAST-B dose-finding results in 2027 for ORKA-001.
Oruka Insider Sells $463K in Stock as Shares Skyrocket 650%, but Here's What Matters for Investors
7,000 shares directly sold for a value of $463,000 on April 15, 2026, at a weighted average sale price of around $66.12 per share. This transaction represented 17% of Joana Goncalves's direct Common Stock holdings, reducing her direct position from 40,377 to 33,377 shares.
Does Oruka Therapeutics, Inc. (ORKA) Have the Potential to Rally 41.51% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 41.5% in Oruka Therapeutics, Inc. (ORKA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Avoro Capital Advisors LLC Makes New Investment in Oruka Therapeutics, Inc. $ORKA
Avoro Capital Advisors LLC purchased a new stake in Oruka Therapeutics, Inc. (NASDAQ: ORKA) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 1,333,340 shares of the company's stock, valued at approximately $25,640,000. Oruka Therapeutics accounts for about 0.3% of Avoro Capital Advisors LLC's
Oruka Therapeutics (NASDAQ:ORKA) Reaches New 1-Year High After Better-Than-Expected Earnings
Oruka Therapeutics, Inc. (NASDAQ: ORKA - Get Free Report) reached a new 52-week high during mid-day trading on Friday after the company announced better than expected quarterly earnings. The company traded as high as $38.75 and last traded at $38.6030, with a volume of 220537 shares. The stock had previously closed at $31.99. The company reported
Oruka Therapeutics: A Potential Future Psoriasis Play
Oruka Therapeutics, Inc. has surged after ORKA-001 showed a half-life four times Skyrizi in Phase 1, targeting the $30B psoriasis market. ORKA-001 and ORKA-002 aim for best-in-class efficacy with dramatically less frequent dosing, potentially shifting the treatment paradigm for chronic skin diseases. Phase 2a EVERLAST-A results for ORKA-001 are expected in 2H26; meaningful revenue is not anticipated until 2031, highlighting ORKA stock's long-term, high-risk profile.
Oruka Therapeutics: ORKA-001 For Psoriasis In Focus As 2026 Phase 2 Data Nears
ORKA's main bet is by targeting psoriasis with ultra-durable biologics like ORKA-001 (IL-23) in Phase 2a and ORKA-002 (IL-17A/F) in Phase 1. ORKA-001 could offer significant clinical benefits with only 1 to 2 doses per year. Its Phase 1 suggests a ~100-day half-life. But interestingly, it's possible that higher exposure may drive higher clearance and potential off-treatment remission.
Wall Street Analysts Predict a 63.59% Upside in Oruka Therapeutics, Inc. (ORKA): Here's What You Should Know
The consensus price target hints at a 63.6% upside potential for Oruka Therapeutics, Inc. (ORKA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
